# GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study

> **NCT04684420** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 81 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Glucophage® XR RM Test
- **DRUG:** Glucophage® XR Reference

## Key facts

- **NCT ID:** NCT04684420
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-22
- **Primary completion:** 2022-03-11
- **Final completion:** 2022-03-11
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04684420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04684420, "GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04684420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*